论文部分内容阅读
为进一步实际评价肿瘤生物免疫治疗在中晚期肿瘤放射介入性等化疗为主的治疗方式中的辅助性治疗价值,本文收集了我科近5年来不同治疗方法且资料较完整并得到随访的同期治疗患者200余例,以回顾性研究,再次探讨了介入化疗辅以综合免疫治疗在控制实体瘤,延长生存期及致机体免疫状况变化方面的临床意义。原发性肝癌112例、肺癌34例、胃肠癌48例、胰胆癌8例、其他12例,均符合相应肿瘤中晚期的诊断标准。所有患者分为:仅行介入
To further evaluate the adjuvant therapeutic value of tumor biological immunotherapy in interventional and other chemotherapy-based treatments for middle and late stage tumors, this article collected the concurrent treatment of different treatment methods in our department in the past 5 years with complete data and follow-up. More than 200 patients, with retrospective studies, once again explored the clinical significance of interventional chemotherapy combined with comprehensive immunotherapy in the control of solid tumors, prolonged survival, and changes in the body’s immune status. 112 cases of primary liver cancer, 34 cases of lung cancer, 48 cases of gastrointestinal cancer, 8 cases of pancreatic and biliary carcinoma, and 12 other cases all met the diagnostic criteria of the corresponding advanced tumor. All patients were divided into: only intervention